Prosecution Insights
Last updated: November 04, 2026
Application No. 18/705,344

MODIFIED FORMS OF AMBROXOL FOR THERAPEUTIC USE

Final Rejection §112
Filed
Apr 26, 2024
Priority
Oct 28, 2021 — provisional 63/272,743 +1 more
Examiner
SAEED, KAMAL A
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Zywie LLC
OA Round
2 (Final)
84%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1023 granted / 1220 resolved
+23.9% vs TC avg
Moderate +10% lift
Without
With
+9.8%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
36 currently pending
Career history
1242
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
9.0%
-31.0% vs TC avg
§102
6.8%
-33.2% vs TC avg
§112
16.6%
-23.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1220 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-11, 13, 15-17, 19-23 and 25 are currently pending in this Application. Claims 15-17, 19-23 and 25 are withdrawn from further consideration by the Examiner, 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention. The withdrawn subject matter is patentably distinct from the elected subject matter as it differs in structure and element and would require separate search considerations. Response to Amendment/Arguments The amendments and remarks filed 08/10/2026 are compliant with the requirements of 37 CFR 1.121(c), accordingly the amendment has been entered. Applicants’ arguments have been fully considered and are addressed below: In regard to the rejections of claims 1-11 and 13 under 35 USC 112(b), second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor regards as the invention, the rejection has been overcome by the amendment filed on 08/10/2026. The rejections have been withdrawn. In regard to the rejection of claims 1-5, 7, 9, and 10 under 35 USC 102(a)(1), as being anticipated by BACHIR LATLI et al, the rejection has been overcome by the amendment filed on 08/10/2026. The rejection has been withdrawn. In regard to the rejection of claims 1-11, and 13 under 35 USC 103(a), as being unpatentable over BACHIR LATLI et al, in view of Dyck et al, US Patent Nos. 6,603,008; 6,221,335; 7,517,990; 6,440,710 and U.S. Patent Publication No. 2007/0082929, the rejection has been overcome by the amendment filed on 08/10/2026. The rejection has been withdrawn. Therefore, claims 1-11 and 13 are allowable. Rejoinder Pursuant to the procedures set forth in MPEP § 821.04(B), claims 15-17, 19-23 and 25, directed to the process of using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, is hereby rejoined and fully examined for patentability under 37 CFR 1.104. Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on May 08, 2026, is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 15-17, 19-23 and 25 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for treating respiratory disease, lysosomal storage disorder and neurological disease, does not reasonably provide enablement for prevention of all respiratory disease, lysosomal storage disorder and neurological disease in general. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention as claimed. Accordingly, the method of claims 44 and 45 are not enabled. The burden of enabling the prevention of any disease/disorder, including the presently claimed respiratory disease, lysosomal storage disorder and neurological disease, would be much greater than that of enabling the treatment of or delaying the progression of, such conditions. In the instant case, the specification does not provide guidance as to how one skilled in the art would accomplish the objective of actually preventing the respiratory disease, lysosomal storage disorder and neurological disease other than by reciting that they may be prevented. Also, no direction is given to identifying a patient who may be at need for such a method, i.e., who is at risk for developing each of the claimed respiratory disease, lysosomal storage disorder and neurological disease. Nor is there any guidance provided as to a specific protocol to be utilized in order to show the efficacy of the presently claimed active ingredients for preventing the claimed respiratory disease, lysosomal storage disorder and neurological disease. Further, it is highly unlikely, and the Office would require experimental evidence to support the contention that the claim specified actives could actually prevent the claimed cardiac dysfunctions by simply administering, by any method, any amount of the claim specified active agents. The specification fails to enable one of ordinary skill in the art to practice and administer the present active agents for preventing any one of the claimed respiratory disease, lysosomal storage disorder and neurological disease. The term “prevention” or “preventing” is essentially synonymous with the term “curing” and both circumscribe methods of treatment having a high degree of success on a “sliding scale” of successful treatments. That is, Applicants are claiming that the claimed actives could actually eradicate each and every one of the claimed respiratory disease, lysosomal storage disorder and neurological disease from ever occurring in any patient and that these dysfunctions would no longer exist given that a population is administered the claimed actives. Since such a level of success in the medical arts is not reasonably possible with most, if any diseases/disorders, especially those having etiologies and pathophysiological manifestations as complex/poorly understood as each and every one of the claimed respiratory disease, lysosomal storage disorder and neurological disease, the specification is viewed as lacking an adequate, detailed enabling disclosure of the same. The quantity of experimentation needed is undue. One of ordinary skill in the art, without direction, would be unable to prevent respiratory disease, lysosomal storage disorder and neurological disease, the method comprising administering the pharmaceutical composition of claim 1 to a subject in need of therapy. One of skill in the art would require undue experimentation to determine the effects of the pharmaceutical composition comprising the compound of formula (I) and how the compositions can be used for the prevention of respiratory disease, lysosomal storage disorder and neurological disease. The level of skill in the art is low. Furthermore, due to the unpredictability in the pharmaceutical art, it is noted that each embodiment of the invention is required to be individually assessed for physiological activity by in vitro and in vivo screening to determine which pharmaceutical compositions exhibit the desired pharmacological activity and which diseases would benefit from this activity. Thus, the specification fails to provide sufficient support of the broad use of the pharmaceutical composition comprising the compound of formula (I) for preventing respiratory disease, lysosomal storage disorder and neurological disease as recited in the instant claims. As a result, necessitating one of skill to perform an exhaustive search in order to practice the claimed invention. The Examiner recommends deleting the term "preventing" and “prevented” from the instant claims in order to overcome the rejection. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. The primary purpose of this requirement of definiteness of claim language is to ensure that the scope of the claims is clear so the public is informed of the boundaries of what constitutes infringement of the patent. A secondary purpose is to provide a clear measure of what applicants’ regard as the invention so that it can be determined whether the claimed invention meets all the criteria for patentability and whether the specification meets the criteria of 35 U.S.C. 112, first paragraph with respect to the claimed invention.", (see MPEP § 2173). Claims 19 and 22 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). Regarding claim 19, the phrases “(including Parkinson’s disease …)” renders the claim indefinite because it is unclear whether the limitation following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 22, the phrases “(including Parkinson’s disease …)” renders the claim indefinite because it is unclear whether the limitation following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Appropriate correction is required. Conclusion Claims 1-11, 13, 15-17, 19-23 and 25 are currently pending. Claims 1-11 and 13 are allowed. Claims 15-17, 19-23 and 25 are rejected. Applicants’ amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for replying to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no case, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAMAL A SAEED whose telephone number is (571) 272-0705. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam C Milligan can be reached at (571)270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000 /Kamal A Saeed/ Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Apr 26, 2024
Application Filed
Apr 22, 2026
Examiner Interview (Telephonic)
May 08, 2026
Non-Final Rejection mailed — §112
Aug 10, 2026
Response Filed
Oct 19, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780792
NOVEL HETEROCYCLIC COMPOUNDS
3y 0m to grant Granted Nov 03, 2026
Patent 12774275
COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES
2y 9m to grant Granted Oct 27, 2026
Patent 12766137
SALT TYPES OF TRICYCLIC TETRAHYDRO ISOQUINOLINE DERIVATIVE
2y 9m to grant Granted Oct 20, 2026
Patent 12758532
SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF
3y 6m to grant Granted Oct 13, 2026
Patent 12751946
TOPICAL ANAESTHETIC COMPOSITION HAVING IMPROVED VASOCONSTRICTOR STABILITY
2y 10m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
84%
Grant Probability
94%
With Interview (+9.8%)
2y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1220 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month